Funding Opportunity Number: HT942525AZRPTRDA
Deadlines
Letter of Intent: June 12, 2025
Final Submission: August 29, 2025
Distinctive Features: This funding opportunity allows for multiple principal investigators (PIs) under the Career Initiation or Transition (CIT) Partnership Option. If utilizing this option, only the initiating PI will submit a pre-application, but each PI will need to submit a full application. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Community collaboration is required.
Leveraging existing resources and cohorts, particularly those that address critical health challenges, is strongly encouraged.
The CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC) is the program office managing this FY25 funding opportunity as part of the Alzheimer’s Research Program (AZRP). Congress initiated the AZRP in 2011 to provide support for research of high potential impact and exceptional scientific merit.
Appropriations for the AZRP from FY11 through FY24 totaled $198M. The FY25 appropriation is $15M.
AZRP Vision Statement: Mitigate the impact of Alzheimer s and related dementias associated with TBI, military, and diverse risks.
AZRP Mission Statement: Fund impactful, solution-oriented research to address critical needs and improve quality of life for Service Members, Veterans, their Families, and the public who are living with Alzheimer s disease and related dementias.
Intent of the Transforming Diagnosis Award The FY25 AZRP Transforming Diagnosis Award (TrDA) is intended to support well-designed research projects that provide significant impact on the AD/ADRD field, Community, and military health. For the purposes of this funding opportunity, the following terms are defined as:
- Military or military health refers to not only members of all components of the Armed Forces, but Veterans, their Families, and other U.S. Department of Defense (DOD) beneficiaries.
- Community encompasses the network of individuals living with an AD/ADRD diagnosis, their care partner(s), families, advocates, and/or other close connections. The CDMRP refers to these individuals as consumers.
The FY25 AZRP TrDA targets research that reduces or overcomes important barriers to obtaining a diagnosis, meaningful disease monitoring, and accurate prognosis. Barriers could include, but are not limited to, technologies, cost, patient access to diagnosis/prognosis technology, diagnosis management, applicability, clinical implementation, relationship to clinical outcome measures, biomarker validation, lack of longitudinal data to inform prediction/prognosis, and more. Applications that do not clearly delineate how the proposed project addresses and/or overcomes current challenges for viable diagnosis and/or prognosis do not meet the intent of this mechanism.
Projects supported by this mechanism must represent a non-incremental advance in the diagnosis or prognosis field. Preliminary data are required. For this mechanism, studies utilizing animal models do not meet the intent of the mechanism and are not allowed.
For more information, please see the opportunity webpage.